Blood And Tissue Screening Tests Top Australia’s IVD Regulatory Scheme
This article was originally published in The Gray Sheet
Executive Summary
In vitro diagnostics that screen for pathogens in the blood supply or in organ and tissue donations would be regulated as highest-risk Class IV devices under the regulatory framework for IVDs proposed by Australia's Therapeutic Goods Administration (TGA)
You may also be interested in...
Australian IVD Framework Proposal Would Broaden Regulatory Oversight
Australia's proposed regulatory structure for in vitro diagnostic devices would bring new regulatory requirements and costs for a number of products that currently are exempt from oversight
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.